The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Open accessAbstract
PD-L1, frequently expressed in human cancers, engages with PD-1 on immune cells and contributes to cancer immune evasion. As such, antibodies blocking the PD-1/PD-L1 interaction reactivate cytotoxic T cells to eradicate cancer cells. However, a majority of cancer patients fail to respond to PD-1/PD-L1 blockade with unclear underlying mechanism(s). Recent studies revealed that PD-L1 expression levels on tumor cells might affect the clinical response to anti-PD-1/PD-L1 therapies. Hence, understanding molecular mechanisms for controlling PD-L1 expression will be important to improve the clinical response rate and efficacy of PD-1/PD-L1 blockade. In this review, we primarily focus on summarizing PD-L1 regulation and its potential roles in regulating anti-tumor immune response, with purpose to optimize anti-PD-1/PD-L1 therapies, benefiting a wider cancer patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationThe DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 2×
“These alterations include, but are not limited to, the loss of the phosphatase and tensin homolog (PTEN), mutation and/or upregulation of PI3K catalytic and regulatory subunits, and the upstream activator K-RAS as well as downstream effectors AKT and PDK1 [69].”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 2×
“Given that PD-L1 is more widely expressed than PD-L2 in normal and tumor cells, more studies focused on exploring physiological and pathological functions for PD-1/PD-L1 engagement as well as how to disrupt their interaction for cancer therapy [12].”
BackgroundFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“It has been reported that there are two ligands for PD-1, PD-L1 (also known as CD274 or B7-H1) and PD-L2 (CD273 or B7-DC) [14, 15].”
Background
Cited by
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Gao, Y., Nihira, N. T., Bu, X., Chu, C., Zhang, J., Kolodziejczyk, A., Fan, Y., Chan, N. T., Ma, L., Liu, J., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0562-4 · Cited by 386
Self-citationBoosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles
Wei, Z., Zhang, X., Yong, T., Bie, N., Zhan, G., Li, X., Liang, Q., Li, J., Yu, J., Huang, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20723-x · Cited by 342
Fang, W., Zhou, T., Shi, H., Yao, M., Zhang, D., Qian, H., Zeng, Q., Wang, Y., Jin, F., Chai, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01786-6 · Cited by 256
Zhang, S., Wang, J., Kong, Z., Sun, X., He, Z., Sun, B., Luo, C., & Sun, J. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121433 · Cited by 255
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122
“Meanwhile, tumoral infiltrations of cytotoxic T cells and Th1 cells and IFN-γ upregulation serve as hallmarks indicating a good response to immune checkpoint inhibitors (71), because IFN-γ can upregulate PD-L1 and MHC-I expression by tumor cells (72).”
BackgroundLiu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00816-w · Cited by 75
Metadata
- Authors
- Zhang, J., Dang, F., Ren, J., & Wei, W.
- Venue
- Trends in Biochemical Sciences
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 43
- Issue
- 12
- Pages
- 1014-1032
- ISSN
- 0968-0004 (ISSN-L)
- OpenAlex
- W2895441403
- Cited by
- 229
- References
- 54
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.